Long-term follow-up study for severe Parkinson's gene therapy
Part of Brain & nervous system clinical trials.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were enrolled in and received IPS101A in the earlier IPS101A-10 clinical trial
- You are willing to provide written consent to participate in this follow-up study
- You agree to attend scheduled follow-up visits and complete study assessments
- You are able to comply with all study-related requirements as judged by the study team
- You are still able to participate (not deceased or otherwise unable to continue)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This study follows up with people who previously received an experimental treatment called RGL-193 for Parkinson's disease. It aims to check how safe and effective the treatment is over a longer period.
This trial is for people with Parkinson's disease or multiple system atrophy (parkinsonian type) who took part in an earlier AB-1005 study. It will continue to monitor your health over time to learn more about the treatment's long-term effects.
This trial tests a new gene therapy (AB-1005) for Japanese adults with moderate Parkinson's disease. It aims to see if the treatment can help improve motor symptoms, especially for people who experience fluctuations in how well their medication works.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.